Uveal Melanoma Market Size, Share and Trends Analysis, By Type, By Diagnosis (Eye Exam, Imaging, Biopsy, and Others), By Therapy, By Route of Administration (Oral, Intravenous, Tropical, and Others), By End-Use (Hospital, Ambulatory Surgical Centers, Cancer Treatment Centers, and Ophthalmology Clinics), and By Region, Forecast 2025-2032

Uveal Melanoma Market Overview and Key Insights:

The uveal melanoma market size reached USD 988.6 million in 2024 and is expected to register a revenue CAGR of 6.6% during the forecast period. Uveal melanoma or eye melanoma is a malignant tumour that develops from melanocytes in the uveal tract. Uveal melanomas result from uncontrolled clonal development of uveal melanocytes.

Market Drivers:

Increasing incidence of eye cancers is a key driver of revenue growth in the uveal melanoma market. According to the American Cancer Society, estimates for primary eye cancer (cancer that begins in the eye) in the United States for 2025 are: approximately 3,140 new malignancies (mostly melanomas) of the eye and orbit (eye socket) (1,620 in men and 1,520 in females) and approximately 490 deaths from malignancies of the eye and orbit (270 men and 220 females). Melanoma is the most prevalent cancer of the eye and orbit in adults, and it affects far more white people than black people.

Advancements in diagnostic imaging is another key driver driving the market revenue growth. Uveal melanoma is diagnosed by ophthalmoscopy, biomicroscopy, and ultrasonography. Magnetic resonance imaging (MRI) is useful for detecting untransparent lenses or subretinal effusions. Furthermore, MRI has become increasingly important in treatment planning, assessing tumor response to radiotherapy, and monitoring patients with uveal melanoma. High-resolution imaging and liquid biopsy techniques have enabled the detection of circulating tumor cells, tumor DNA, and microRNAs. Radiation therapy (plaque brachytherapy) and surgical techniques are among the standard therapies.

On March 2025, IDEAYA Biosciences, Inc., a precision medicine oncology company dedicated to the discovery and development of targeted therapeutics, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to darovasertib, a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma (UM) for whom enucleation has been recommended.

Market Opportunity:

Expansion of research into gene-based and personalized medicine approaches acts as opportunities for uveal melanoma market. Novel diagnostic biomarkers, such as circulating tumor cells, DNA, and extracellular vesicles, are presented as promising non-invasive methods for early identification and monitoring. Molecular stratification has enhanced the clinical management of UM by allowing for more individualized treatment and prognosis. Innovations in liquid biopsy techniques, the discovery of novel biomarkers, and the introduction of targeted therapeutics such as Tebentafusp represent significant advances in the field; yet, the search for more effective treatments continues. Furthermore, new advances in drug delivery technologies, including as nanoparticles and virus-like drug conjugates, combined with the use of selective internal radiation therapy, are potential techniques for improving the precision and efficacy of UM treatment.

Recent Trends:

Emerging trends include rise of precision & targeted therapies, expansion of immunotherapy approaches, advanced diagnostic & prognostic tools, innovative ocular drug-delivery systems, and digital health & remote monitoring integration.

Artificial intelligence (AI) has proven to be a vital asset in cancer, particularly its use in uveal melanoma (UM). AI technologies such as machine learning (ML), deep learning (DL), and convolutional neural networks (CNNs) play critical roles in medical imaging and diagnosis. These tools are designed to manage enormous datasets, identify complicated patterns, and offer insights to aid clinical decision-making.

Prognostication in uveal melanoma is one of the most common applications of machine learning in this field. For example, deep learning-based analysis of digital pathology images has considerable potential, especially for predicting the gene expression profile (GEP) of UM tumors. UM is an uncommon but aggressive cancer of the eye, and its precise diagnosis and prognosis evaluation are critical for selecting suitable patient treatment and management.

On May 2025, Topcon Healthcare, Inc., a global leader in robotic diagnostics and digital health solutions, has announced the introduction of the Institute of Digital Health (IDHea), an ocular data-as-a-service platform that aims to accelerate AI research and digital health innovation. IDHea enables rapid and safe access to unique real-world and clinical trial datasets, resulting in advances in healthcare applications that enhance outcomes for both ocular and systemic disorders. IDHea enables researchers and innovators to push the boundaries of digital healthcare solutions.

Restraints & Challenges:

Uveal melanoma (UM), the most prevalent primary intraocular malignancy in adults, presents a unique therapeutic challenge due to its high risk of liver metastases and poor response to standard therapy. Despite the growing field of immunotherapy in oncology, progress in treating metastatic uveal melanoma (mUM) remains modest, and no globally approved standard of care has been established.

While recent breakthroughs in uveal melanoma (UM) diagnosis and therapy indicate great therapeutic potential, its practical application has severe limitations. Two important challenges continue to impede the deployment of these innovations: excessively high costs associated with new diagnostic tools and novel medicines, as well as unequal global access across healthcare systems.

Type Segment Insights and Analysis:

Based on the type, the uveal melanoma market is segmented into choroidal melanoma, ciliary body melanoma, iris melanoma, conjunctival melanoma, eyelid melanoma, and orbital melanoma.

Choroidal melanoma segment contributed the largest market share in 2024. Uveal melanoma is a malignant tumor that develops from melanocytes in the uveal tract (iris, ciliary body, or choroid). It is the most common primary intraocular tumor in adults, with an age-adjusted prevalence of 5.1 per million. The choroid is the most prevalent location implicated, accounting for 90% of all uveal melanomas. Melanomas developing within the ciliary body account for 7%, while melanomas of the iris account for 2%. Choroidal melanocytic tumors with no causes have a 3% risk of growing in 5 years and are most likely choroidal nevi. Approximately 6% of the Caucasian population has a choroidal nevus. Choroidal nevi develop into choroidal melanoma in approximately 1 in 5000 to 1 in 8800 cases.

On September 2024, Aura Biosciences, Inc., a clinical-stage biotechnology company developing precision therapies for solid tumors that preserve organ function, has announced positive Phase 2 end-of-study results for bel-sar (AU-011) in the first-line treatment of early-stage choroidal melanoma (CM), a vision-threatening ocular cancer. The Phase 2 research (NCT04417530) is an open-label, ascending single and repeat dose escalation experiment in patients with early-stage CM (small CM and undetermined lesions) aimed at determining the safety, tolerability, and efficacy of up to three cycles of bel-sar therapy.

Diagnosis Segment Insights and Analysis:

Based on the diagnosis, the uveal melanoma market is segmented into eye exam, imaging, biopsy, and others.

Imaging segment contributed the largest market share in 2024. Intraocular uveal melanoma requires imaging to be diagnosed and managed properly. A successful imaging application will usually involve numerous modalities, including as color photography, ocular ultrasonography, fluorescein angiography, and optical coherence tomography. Ocular magnetic resonance imaging (MRI) has emerged as a significant technique in the diagnosis, treatment selection, and follow-up of patients with UM. Similarly, for cancers in other body regions, MRI can reduce uncertainty in ocular PT, contributing to radiation-induced adverse effects mitigation techniques. The amount of overestimation is determined by several parameters, including pupil diameter, tumor height, and the existence of retinal detachment or hemorrhage. As a result, for anteriorly situated cancers, MRI is a more reliable tool for determining the tumor’s posterior extension than traditional visual procedures.

On May 2024, the Melanoma Research Alliance (MRA), the world’s premier non-profit supporter of melanoma research, announced an USD 12.6 million investment to support melanoma research by more than 30 experts at leading academic and medical institutions in the United States and abroad. While current medications benefit half of advanced melanoma patients, MRA-funded researchers are actively investigating new therapeutics and innovative immunological interventions to bridge the gap for those whose melanomas are resistant to existing treatments.

Therapy Segment Insights and Analysis:

Based on the therapy, the uveal melanoma market is segmented into radiation, laser therapy, immunotherapy, chemotherapy, surgical treatment, and others.

Radiation segment contributed the largest market share in 2024. Cancer segment is further sub-segmented into plaque radiotherapy (brachytherapy), proton beam radiotherapy, and stereotactic radiosurgery. Uveal melanoma is the most common type of primary malignant intraocular tumor in adults. Radiation oncologists use advanced techniques to deliver high doses of radiation directly to cancer cells while minimizing exposure to surrounding healthy tissue, thereby reducing side effects, and enhancing treatment outcomes.

Current effective treatment options include proton beam radiotherapy, plaque brachytherapy (using isotopes such as Iodine-125, Ruthenium-106, Palladium-103, and Cesium-131), as well as stereotactic radiotherapy and radiosurgery (Gamma Knife, CyberKnife, LINAC). Clinicians may prefer proton beam therapy over brachytherapy when the tumor’s size, shape, or position prevents full plaque coverage. They often choose this approach for larger tumors or those located near the optic nerve. However, limited availability of specialized equipment restricts access to proton beam therapy, since not all cancer centers offer it.

On August 2023, the U.S. Food and Drug Administration has approved the HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), which delivers melphalan directly to the liver, for the treatment of adult patients with uveal melanoma that has spread to the liver but cannot be surgically removed. Eligible patients must have liver involvement affecting less than 50% of the organ and no cancer outside the liver, or only limited extrahepatic disease confined to the bone, lymph nodes, subcutaneous tissue, or lungs that can be treated with surgery or radiation.

Geographical Outlook:

Uveal melanoma market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Uveal Melanoma Market:

North America is registered to have highest market share in uveal melanoma market in 2024. This is mainly driven by increasing incidence of eye cancers and development of targeted therapies and immunotherapies. Uveal melanoma is a rare type of melanoma that arises from melanocytes in the uvea, accounting for only about 5% of all instances of melanoma in the United States. Up to half of patients with uveal melanoma will develop metastatic disease, which can be fatal. Ocular melanoma is more common among fair-skinned people. Smoking raises the risk of the illness, which primarily affects persons in their 60s.

On February 2024, Immunocore Holdings plc, a commercial-stage biotechnology company, announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb to study Immunocore’s ImmTAC bispecific TCR (T cell receptor) candidate targeting PRAME HLA-A02, IMC-F106C, in combination with Bristol Myers Squibb’s nivolumab in first-line advanced cutaneous melanoma. Immunocore will sponsor and fund the registrational Phase 3 clinical trial of IMC-F106C in combination with nivolumab in first-line advanced cutaneous melanoma (PRISM-MEL-301), while Bristol Myers Squibb will furnish nivolumab.

Asia Pacific Uveal Melanoma Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by increasing incidence of eye cancers, advancements in diagnostic imaging, and development of targeted therapies and immunotherapies. In India, one in every 15,000 to 18,000 live births develops this type of cancer. Uveal melanoma is common in adults (the average age at diagnosis is 45-55). About 30%–40% of uveal melanomas present no symptoms at diagnosis and are usually detected incidentally during routine eye examinations. The incidence is higher in people with light pigmentation and substantially lower in Asian and black populations.

On April 2025, Astellas Pharma Inc. and the Japanese Foundation for Cancer Research established a strategic alliance to enhance translational and clinical oncology research. The agreement combines Astellas’ unique scientific, translational, and clinical experience with JFCR’s strength as a world-class comprehensive cancer research center to accelerate the development of innovative therapeutics for patients with tumors that are resistant to conventional therapies.  

Europe Uveal Melanoma Market:

Europe is expected to have considerable market share in 2024. On June 2025, Er-Kim, a global pharmaceutical company focused on bringing innovative therapies to market, announced its appointment by Immunocore as the distribution and commercialization partner for KIMMTRAK. The partnership covers the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in Turkey, as well as in the Middle East, North Africa, Caucasus, and Commonwealth of Independent States (CIS) regions.

Competition Analysis:

The uveal melanoma market is characterized by a fragmented structure, with several players competing across various segments and regions. list of major players included in the uveal melanoma market report are:

• Eli Lilly & Co.
• Novartis
• Bristol-Myers Squibb Company
• Hoffmann-La Roche Ltd
• Immunocore Holdings plc
• iOnctura
• IDEAYA Biosciences
• Aura Biosciences, Inc.
• Amgen
• Pfizer Inc.
• Delcath Systems, Inc.
• Merck
• Castle Biosciences, Inc.
• Modulation Therapeutics
• Regeneron Pharmaceuticals Inc.

Strategic Developments in Uveal Melanoma Market:

• In August 2025, University of Liverpool has created the Eye Cancer Artificial Intelligence Digital Bioresource (EYE-CAN-AID), which aims to improve early diagnosis of uncommon eye tumors. The event featured Roche Diagnostics technology, including a cutting-edge, high-resolution scanner for analyzing eye cancer cells and tissues. The VENTANA DP 600 digital pathology slide scanner will be critical in producing high-quality digital images of rare ocular (eye) cancers for subsequent interpretation, ultimately aiding patients by enhancing diagnostic and therapy approaches.
• In November 2023, Aura Biosciences, Inc., a clinical-stage biotechnology company developing a new class of virus-like drug conjugate (VDC) therapies for various cancer indications, announced that the U.S. Food and Drug Administration (FDA) has granted agreement under a Special Protocol Assessment (SPA) for the design and planned analysis of CoMpass, its global Phase 3 trial evaluating bel-sar as a first-line treatment for adult patients with early-stage choroidal melanoma (CM).

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of The Uveal Melanoma Market Report:

The Uveal Melanoma market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Type Outlook (Revenue, USD Million; 2022-2032)
  • Choroidal Melanoma
  • Ciliary Body Melanoma
  • Iris Melanoma
  • Conjunctival Melanoma
  • Eyelid Melanoma
  • Orbital Melanoma

• Diagnosis Outlook (Revenue, USD Million; 2022-2032)
  • Eye Exam
    • Ophthalmoscopy
    • Slit-Lamp Biomicroscopy
    • Others
  • Imaging
    • Ultrasound
    • Flurorescein Angiography
    • Fundus Autoflurorescence
    • Optical Coherence Tomography
    • Others
  • Biopsy
  • Others

• Therapy Outlook (Revenue, USD Million; 2022-2032)
  • Radiation
    • Plaque Radiotherapy (Brachytherapy)
    • Proton Beam Radiotherapy
    • Stereotactic Radiosurgery
  • Laser Therapy
    • Transpupillary Thermotherapy (TTT)
    • Photocoagulation
  • Immunotherapy
    • Tebentafusp (Kimmtrak)
    • Pembrolizumab (Keytruda)
    • Nivolumab (Opdivo)
    • Ipilimumab (Yervoy) 
  • Chemotherapy
    • Rituximab
    • Ibritumomab
    • Imatinib
    • Sorafenib
    • Others
  • Surgical Treatment
    • Enucleation
    • Iridectomy
    • Iridocyclectomy
    • Exenteration
  • Others

• Route of Administration Outlook (Revenue, USD Million; 2022-2032)
  • Oral
  • Intravenous
  • Tropical
  • Others

• End-Use Outlook (Revenue, USD Million; 2022-2032)
  • Hospital
  • Ambulatory Surgical Centers
  • Cancer Treatment Centers
  • Ophthalmology Clinics

• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the Uveal Melanoma market report